Drug Profile
Cadazolid - Actelion Pharmaceuticals
Alternative Names: ACT-179811Latest Information Update: 24 Apr 2018
Price :
$50
*
At a glance
- Originator Actelion Pharmaceuticals
- Class Anti-infectives; Antibacterials; Carboxylic acids; Oxazolidinones; Small molecules
- Mechanism of Action Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Clostridium difficile infections
Most Recent Events
- 31 Mar 2018 Discontinued - Phase-II for Clostridium difficile infections in United Kingdom and Sweden (PO)
- 31 Mar 2018 Discontinued - Phase-II/III for Clostridium difficile infections (In adolescents, In children, In infants, In neonates) in USA (PO)
- 31 Mar 2018 Discontinued - Phase-III for Clostridium difficile infections in Croatia, Chile, Peru, Argentina, Netherlands, France, Brazil, Slovakia, Poland, Puerto Rico, Spain, Romania, Italy, Germany, Australia, South Korea, Israel, Hungary, Greece, Canada, Belgium, Czech Republic and USA (PO)